Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.

Pharma Pulse: HHS Bypasses PBMs and the Reality of GLP-1 Weight Regain

Articles

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.

CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

Why Direct-to-Patient Is the Pharma Industry’s Next Power Move

In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and BoomRx launches a needle-free nanoemulsion for weight loss.

Pharma Pulse: Global AI Alignment, the TrumpRx Pivot, and Nano-Delivery GLP-1s

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity accelerates.

Evaluate’s 2026 Pharma Forecast Signals Cautious Recovery, Rising M&A, and GLP-1 Market Shifts

In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.

Pharma Pulse: Amazon Pharmacy Sells Oral Wegovy, J&J’s Billion-Dollar Hub, and the Debt-Housing Crisis

Novo Nordisk’s newly approved oral semaglutide is now available nationwide through Amazon Pharmacy with insurance and cash-pay options.

Amazon Pharmacy Adds FDA-Approved Wegovy Pill, the First Oral GLP-1 for Weight Loss

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

Johnson & Johnson Joins TrumpRx to Lower Drug Prices, Secures Tariff Exemption

Backed by Frazier Healthcare Partners and strengthened by the acquisition of eBlu Solutions, CareTria aims to accelerate patient access by combining provider technology, digital enrollment, and multi-modal fulfillment into a single end-to-end platform.

Knipper Health Rebrands as CareTria to Expand Integrated Therapy Initiation Platform

Videos

In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, points out that from biosimilars and site-of-care shifts to AI, value-based reimbursement, and potential legislative action, market deflators—not simple cost shifting—will determine whether affordability improves across employer-sponsored plans, Medicaid, and Medicare.

Market Access